Search

Interpersonal violence is a significant public health and human rights concern. People living with severe mental illness are especially vulnerable. The Sustainable Development Goals 2030 Agenda aims to end violence. To this end, we gathered information on the prevalence and factors associated with interpersonal violence among one of the most impacted groups: individuals with severe mental illness at Butabika Hospital in Kampala, Uganda. We conducted a cross-sectional study in 2020, including individuals 18 years or older. Data was collected through a socio-demographics questionnaire and nine questions from the modified My Exposure to Community Violence Questionnaire. The assessment evaluated physical or sexual violence experience, frequency, and perpetrator identity. The data was analyzed using STATA version 12 through simple logistic regression to determine the correlation between a single exposure and the outcome of interest, with a significance level of 5%. Among 385 participants, the past year prevalence of overall reported interpersonal violence was about 34%, while physical and sexual reported interpersonal violence were approximately 29% and 11%, respectively. Participants who had perpetrated physical violence had higher odds of experiencing reported interpersonal violence. With increasing age, the odds of experiencing reported interpersonal violence decreased; compared to those aged 18–24 years, those aged 35–44 years had AOR = 0.31 (95% CI: 0.14–0.70, p = 0.005), and those aged 45 years and above had AOR = 0.34 (95% CI: 0.15–0.80, p = 0.013). Reported interpersonal violence was high among the participants. While individuals of older age had lower odds of reporting interpersonal violence, those who had perpetrated physical violence in the past year had higher odds. Screening for interpersonal violence among young patients is recommended. Psycho-education on preventing physical violence should be provided, especially to younger adults. The Ministry of Health should address violence against individuals with mental illness through mass sensitization. A prospective study could investigate risk and protective factors. [ABSTRACT FROM AUTHOR]

Background: Human Papilloma Virus (HPV) vaccination can prevent more than 90% of cancers caused by HPV. Although this vaccination is recommended and provided at no cost to all adolescent girls aged 9 to19 years in Uganda, its uptake remains low. We sought to determine the uptake of, and factors associated with HPV vaccination among adolescent girls living with HIV in Uganda. Methods: We conducted an explanatory sequential mixed methods study, among adolescent girls living with HIV, attending HIV care at the Mulago ISS HIV clinic in Kampala, Uganda. We administered a structured questionnaire to elicit data on HPV vaccination and its covariates to a systematic random sample of 264 adolescent girls with HIV. A participant who had received all the three recommended HPV vaccine doses was classified as fully vaccinated. We then conducted four focus group discussions among adolescent girls living with HIV (n = 32), eight in-depth interviews among their parents and five Key informant interviews among their healthcare providers. We conducted descriptive statistics and logistic regression analyses for the quantitative data before thematic analysis for the qualitative data. Result: Of 264 adolescent girls, 31% (83/264) had at least one HPV vaccine dose; 22% (59/264) two doses, while 8.0% (21/264) were fully vaccinated (received three doses). While most participants received their first and second doses (48% (40/83)) and 57.6% (34/59), respectively) from school, the largest number of participants (47.1% (12/21)) received their third dose at community outreaches. Participants who received counseling from community members were three times more likely to get fully vaccinated compared to those who did not receive counseling (aOR 3.28, Cl:1.07–10.08, P = 0.038). From the qualitative follow-up, three major themes were identified: (1): Limited information about HPV vaccination, which gave room for misconceptions and doubts about the vaccine; (2) Parental influence on adolescent decisions was strong despite parents having limited knowledge about HPV vaccination and (3) Inadequacy of HPV vaccination services at the hospital and in the schools. Conclusion: Full HPV vaccination was low among adolescent girls living with HIV. Counseling of the adolescents by community members, alongside HPV vaccination community outreaches, provided a platform for vaccination. There should be strategies to provide adequate information about HPV vaccine to health workers, parents, and the adolescents. In addition to schools, community-based initiatives, including outreaches and lay-health workers can be utilized to improve HPV vaccine uptake among girls with HIV. [ABSTRACT FROM AUTHOR]

Introduction: Dolutegravir (DTG) is a second‐generation integrase strand transfer inhibitor that is recommended by the World Health Organization as the preferred first‐line and second‐line antiretroviral therapy (ART) in patients with HIV. In 2018, Uganda started using DTG‐based regimens as the preferred first‐line ART. However, concerns regarding the potential neurotoxicity of DTG have been increasing. Data on the occurrence of neuropsychiatric adverse events (NPAEs) and the associated factors among adult patients who are initiated on or switched to DTG‐based first‐line or second‐line ART in Uganda are limited. Objective: This study aimed to determine the prevalence of NPAEs among adult patients on DTG and the factors associated with their occurrence. Methods: We conducted a cross‐sectional study using questionnaires administered by a trained research assistant between 15 November 2021 and 15 December 2021. The study included patients aged ≥18 years with HIV who were either initiated on or switched to a DTG‐based ART regimen between 1 January 2018 and 31 October 2021. Informed consent and data were collected from 892 participants attending Mulago ISS clinic, including data on age, sex, marital status, disclosure status, current regimen, duration on ART, concurrent illness, concurrent medications, year of switch to DTG, duration on DTG, whether the onset of NPAEs was immediate or delayed, history of alcohol use or smoking, level of education, report of NPAEs while on DTG, and history of NPAEs while on previous regimen. Data were entered into Epidata version 4.6.0.2 then exported to Stata version 14 for analysis. Results: Of the 892 adults on DTG attending Mulago ISS clinic, 41.7% (95% confidence interval [CI] 38.5%–44.9%) experienced at least one NPAE. DTG duration in years (adjusted prevalence [aPR] = 1.21, p = 0.024), disclosure status (aPR = 1.40, p = 0.042), concurrent medications (aPR = 1.31, p = 0.026), year of switch to DTG, and concurrent illness were associated with an increased occurrence of NPAEs. Conclusions: The prevalence of NPAEs was higher than that reported by any clinical trial. About 9.1% of participants had experienced severe to life‐threatening NPAEs that required intervention from a healthcare professional to improve tolerability. The high prevalence requires that clinicians screen for NPAEs at very visit and reassure patients to maximize the benefits of long‐term ART. [ABSTRACT FROM AUTHOR]